ADP-ribose-acceptor hydrolase 2(Arh2) deficiency results in cardiac dysfunction, tumorigenesis, inflammation, and decreased survival
preprint
OA: closed
Abstract
ADP-ribosylation is a reversible reaction with ADP-ribosyltransferases catalyzing the forward reaction and ADP-ribose-acceptor hydrolases (ARHs) hydrolyzing the ADP-ribose acceptor bond. ARH2 is a member of the 39-kDa ARH family (ARH1-3), which is expressed in heart and skeletal muscle. ARH2 failed to exhibit any in vitro enzymatic activity. To determine its possible in vivo activities, Arh2 -knockout (KO) and - heterozygous (Het) mice were generated using CRISPR-Cas9. Arh2 -KO mice exhibited decreased cardiac contractility by MRI, echocardiography and dobutamine stress with cardiomegaly and abnormal motor function. Arh2 -Het mice showed results similar to those seen in Arh2 -KO mice except for cardiomegaly. Arh2 -KO and -Het mice and mouse embryonic fibroblasts (MEFs) developed spontaneous tumors and subcutaneous tumors in nude mice. We identified 13 mutations in Arh2 -Het MEFs and heterozygous tumors, corresponding to human ARH2 mutations in cancers obtained from COSMIC. Of interest, the L116R mutation in Arh2 gene plays a critical role in aggressive tumorigenesis in nude mice, corresponding to human ARH2 mutations in stomach adenocarcinoma. Both genders of Arh2 -KO and -Het mice showed increased unexpectedly deaths and decreased survival rate during a 24-month observation, caused by tumor, inflammation, non-inflammation (e.g., cardiomegaly, dental dysplasia), and congenital diseases. Thus, Arh2 plays a pivotal role in cardiac function, tumorigenesis, inflammation, and overall survival.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (45)
- doi:10.1016/b978-0-12-152820-1.50010-9 via crossref
- doi:10.1038/nrm3376 via crossref
- doi:10.3390/cells4040569 via crossref
- doi:10.1074/jbc.273.37.23617 via crossref
- doi:10.1007/s00726-010-0676-2 via crossref
- doi:10.1016/s0021-9258(19)86783-2 via crossref
- doi:10.1073/pnas.75.8.3621 via crossref
- doi:10.1093/nar/gkz120 via crossref
- doi:10.1038/s41467-018-05588-5 via crossref
- doi:10.1038/s41467-019-08859-x via crossref
- doi:10.1038/nsmb.2521 via crossref
- doi:10.1074/jbc.m110.206771 via crossref
- doi:10.1073/pnas.82.17.5603 via crossref
- doi:10.1016/s1054-3589(08)60277-x via crossref
- doi:10.1634/stemcells.2006-0054 via crossref
- doi:10.3389/fgene.2021.691272 via crossref
- doi:10.1016/j.ydbio.2016.05.006 via crossref
- doi:10.1021/acschembio.9b00429 via crossref
- doi:10.3390/cells11233853 via crossref
- doi:10.1073/pnas.0607911103 via crossref
- doi:10.1074/jbc.m111.237636 via crossref
- doi:10.7554/elife.28533 via crossref
- doi:10.1007/bf00928452 via crossref
- doi:10.1038/s41467-017-02253-1 via crossref
- doi:10.1074/jbc.m510290200 via crossref
- doi:10.1016/j.chembiol.2018.11.001 via crossref
- doi:10.1038/s41467-019-12682-9 via crossref
- doi:10.1371/journal.pone.0235433 via crossref
- doi:10.1158/1541-7786.mcr-21-0874 via crossref
- doi:10.1016/j.exer.2017.10.007 via crossref
- doi:10.1038/35077213 via crossref
- doi:10.3390/ijms21249682 via crossref
- doi:10.1111/dmcn.14975 via crossref
- doi:10.1007/s11010-016-2849-0 via crossref
- doi:10.1038/nrdp.2016.59 via crossref
- doi:10.1161/circulationaha.115.020324 via crossref
- doi:10.1016/s0895-4356(00)00363-2 via crossref
- doi:10.1161/cir.0000000000000296 via crossref
- doi:10.1177/019262339502300605 via crossref
- doi:10.1038/s41368-018-0012-3 via crossref
- doi:10.1038/s41368-018-0041-y via crossref
- doi:10.1158/1538-7445.am2011-5327 via crossref
- doi:10.1172/jci.insight.97898 via crossref
- doi:10.1016/j.cell.2013.04.025 via crossref
- doi:10.1128/mcb.00302-07 via crossref
Source provenance
- crossref
- last seen: 2026-08-22T06:23:43.890402+00:00
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-09-14T06:35:54.356137+00:00